Pharmacological regulation of thrombin;La thrombine et sa regulation pharmacologique

Presse Medicale

Volumn 27, Issue SUPPL. 2, 1998, Pages 22-27

  Guillin, M C ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; FIBRIN; FIBRINOGEN; GLYCOPROTEIN IB; GLYCOSAMINOGLYCAN; HEPARIN; HEPARINOID; HIRUDIN; THROMBIN; THROMBIN INHIBITOR; THROMBOMODULIN; FIBRINOLYTIC AGENT;

CONFERENCE PAPER; DRUG MECHANISM; HUMAN; THROMBOCYTOPENIA; THROMBOGENESIS; AMINO ACID SEQUENCE; CHEMISTRY; GENETIC VARIABILITY; GENETICS; MOLECULAR GENETICS; PHYSIOLOGY; REVIEW;

AMINO ACID SEQUENCE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MOLECULAR SEQUENCE DATA; THROMBIN; VARIATION (GENETICS);

EID: 0032090938     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Guillin MC, Bouton MC, Bezeaud A, Jandrot-Perrus M. Thrombin interaction with vascular and non vascular cells. Atherosclerosis 1997 ; sous presse.
2. Harker LA, Hanson SR, Kelly AB. Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997 ; 78:736-41.
3. Guillin MC, Jandrot-Perrus M, Bezeaud A. La thrombine: molécule multifonctionnelle. STV 1993 ; 5:587-97.
4. Bevers EM, Comfurius P, Zwaal RF. Platelet procoagulant activity: physiological significance and mechanisms of exposure. Blood Rev 1991 ; 5:146-54.
5. Kaplanski G, Farigoule M, Boulay V et al. Thrombin induces endothelial type II activation in vitro. IL-1 and TNF-α-indépendant IL-8 secretion and E-selectin expression. J Immunol 1997 ; 158:5435-41.
6. Lorant DE, Patel KD, Mc Intyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991 ; 115:223-34.
7. Malik AB, Fenton JW. Thrombin-mediated increase in vascular endothelial permeability. Semin Thromb Hemost 1992 ; 18:193-9.
8. Rabiet MJ, Plantier JL, Rival Y, Genoux Y, Lampugnani MG, Dejana E. Thrombin-induced increase in vascular permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 1996 ; 16:488-96.
9. Grand RJA, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J 1996 ; 313:353-68.
10. Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human a-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry and structure-function relationships. Protein Science 1992 ; 1:426-71.
11. Berliner LJ, Shen YYL. Physical evidence of an apolar binding site near the catalytic center of human a-thrombin. Biochem 1977 ; 16:4622-6.
12. Grutter MG, Priestle JP, Rahuel J et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibitor. Embo J 1990 ; 9:2361-5.
13. Gan ZR, Li Y, Chen Z, Lewis SD, Shafer JA. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem 1994; 269:1301-5.
14. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991 ; 64:1057-68.
15. Rasmussen UB, Vouret-Craviari V, Jallat S et al. C-DNA cloning and expression of a hamster a-thrombin receptor coupled to Ca2+ mobilization. FEBs Lett 1991 ; 288:123-8.
16. Pipili-Synetos E, Gershengorn MC, Jaffe EA. Expression of functional thrombin receptors in xenopus oocytes injected with human endothelial cell in RNA. Biochem Biophys Res Commun 1990 ; 171:913-19.
17. Brass LF, Molino M. Protease-activated G protein coupled receptors on human platelets and endothelial cells. Thromb Haemost 1997 ; 78:234-41.
18. Vu T-KH, Wheaton VI, Hung DT, Charo I, Coughlin SR. Domains specifying thrombin-receptor interaction. Nature 1991 ; 353:674-7.
19. Coughlin SR, Vu T-KH, Wheaton VI. Characterization of a functional thrombin receptor. Issues and opportunities. J Clin Invest 1992 ; 89:351-55.
20. Verrall S, lshii M, Chen M, Wang L, Tram T, Coughlin SR. The thrombin receptor second cytoplasmic loop confers coupling to Gq-like G proteins in chimeric receptors. Additional evidence for a common transmembrane signaling and G protein coupling mechanism in G protein-coupled receptors. J Biol Chem 1997 ; 272:6898-902.
21. Ishihara H, Connolly AJ, Zeng D et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 1997 ; 386:502-6.
22. Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. J Clin Invest 1984 ; 74:341-50.
23. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation b antithrombin III-independant inhibitors. J Clin Invest 1990 ; 86:385-91.
24. Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudin. Thromb Haemost 1990 ; 64:344-8.
25. Gusto Ilb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996 ; 335:775-82.
26. Kelly AB, Marzec UM, Krupski W et al. Hirudin interruption by heparin-resistant arterial thrombus formation in baboons. Blood 1991 ; 77:1006-12.
27. Rao AK, Sun L, Chesebro JH et al. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment 1.2 in unstable angina. A multicenter trial. Circulation 1996 ; 94:2389-95.
28. Zodhelyi P, Bichler J, Owen GO et al. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994 ; 90:2671-8.
29. Nowak G, Bucha E, Brauns I, Czerwinski R. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Wien Klin Wochenschr 1997 ; 109:354-8.
30. Harenberg J, Huhle G, Piazolo L, Wang LU, Heene DL. Anticoagulation in patients with heparin-induced thrombocytopenia type II. Semin Thromb Hemost 1997 ; 23:189-96.
31. Schiele F, Vuillemenot A, Kramarz P et al. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995 , 50:20-5.
32. Lunven C, Gauffeny C, Lecoffre C, O'Brien DP, Roome NO, Berry CN. Inhibition by Argatroban, a specific thrombin inhibitor of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996 ; 75:154-60.
33. Cook JJ, Sitko GR, Bednar B et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimented arteriall thrombosis in the African green monkey. Circulation 1995 ; 91:2961-71.
34. Waxman L, Smith DE, Arkuri KE, Vlasuk GP. Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990 ; 248:593-6.
35. Nutt EM, Jain D, Lenny AB, Schaffer L, Siegl PK, Dunwiddie CT. Purification and characterization of recombinant antistasin: a leech-derived inhibitor of coagulation factor Xa. Arch Biochem Biophys 1991 ; 285:37-44.
36. Petitou M, Duchaussoy P, Jaurand G et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997 ; 40:1600-7.
37. Haskel EJ, Torr SR, Day KC et al. Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 1991 ; 84:821-7.
38. Jang Y, Guzman LA, Lincoff AM et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995 ; 92:3041-50.
39. Gomi K, Zushi M, Honda G et al. Antithrombotic effect of recombinant human thrombomodulin on thrombin-induced thromboembolism in mice. Blood 1990 ; 75:1396-401.
40. Gruber A, Hanson SR, Kelly AB et al. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation 1990 ; 82:578-82.
41. Gibbs CS, Coutre SE, Tsiang M et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995 ; 378:413-16.
42. Tsiang M, Paborsky LR, Li WX et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochem 1996 ; 35:16449-57.